Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223 dichloride

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Bexsero halved UK meningitis B cases in first year, says study

GSK hopes success of its UK vaccination campaign will encourage replication worldwide

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

- PMLiVE

Vectura’s Flutiform flunks phase III COPD test

But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

- PMLiVE

Teva gets EU nod for severe asthma drug Cinqaero

Once-monthly dose able to improve asthma control

- PMLiVE

AstraZeneca adds cardiovascular resources to online diabetes programme

Expansion of Fit2Me also includes new Apple and Android mobile apps

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

AstraZeneca AZ global R&D corporate HQ

AZ’s selumetinib stumbles at last fence in lung cancer

Phase III trial shows failure to improve patient survival rates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links